ARTL News & Events

Artelo Biosciences announced that on February 27, 2026, Artelo's Board of Directors approved a 3-for-1 reverse stock split of the Company's common stock. The Company's common shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market commencing at the market open, March 10, 2026. The Board of Directors determined the 3-for-1 ratio to be appropriate in order to increase the price per share of the Common Stock to improve its marketability and liquidity.

Artelo Biosciences commented on the White House's recent Executive Order establishing a Medicare pilot program to support reimbursement and structured data collection for cannabidiol, CBD, products. Artelo views the Administration's action as a "significant milestone" in the recognition of CBD's therapeutic potential. The Company believes the federal government's "emphasis on data collection to inform future research and potential expansion to Medicaid and broader patient populations highlights a growing demand for safe, effective, and well-characterized CBD therapies," the company said.